Location: Various — Geneva, Atlanta, Wuhan (Alleged) — 2002–2019
Present Day: Archive Verification, WHO Internal Documents (Leaked)
The Trader first heard about engineered viruses in 2002.
He was in Geneva, meeting with a banker who handled accounts for pharmaceutical companies. Over lunch at a private club overlooking the lake, the banker mentioned a new trend: governments were funding research into pathogens that could be used as weapons.
"Biological warfare?" the Trader asked.
"Not exactly. More like... population control. There are people who believe the world has too many humans. They see disease as a solution."
The Trader thought about the girl in Lebanon. About the empty villages in Nigeria. About all the death he had already facilitated.
"And they're developing these things?"
"In labs. Secret labs. Funded by governments, by corporations, by private foundations. They call it 'biodefense research.' But the line between defense and offense is very thin."
The Trader filed this information away. It seemed remote, abstract, unrelated to his world of money and weapons.
He was wrong.
THE SCIENTIST
In 2005, the Trader met a man named Dr. Francois Duvalier.
Duvalier was a French microbiologist, trained at the Pasteur Institute, now working for a private research company in Switzerland. He was brilliant, arrogant, and utterly without conscience. The Trader was introduced to him by a mutual contact who thought they might have business to discuss.
They met in Duvalier's office, a sterile space filled with microscopes and petri dishes. Duvalier was small, intense, with eyes that seemed to look through you rather than at you.
"You move money," Duvalier said. "I've been told you can make things disappear."
"I can."
"Good. I need funding. Research funding. The kind that doesn't appear on any balance sheet."
"What kind of research?"
Duvalier smiled. It was not a pleasant expression.
"The kind that could save humanity. Or end it. Depending on your perspective."
The Trader listened as Duvalier explained his work. He was developing a virus—a modified influenza strain—that could be tailored to target specific populations. By tweaking the genetic code, he could make it more lethal to people with certain genetic markers. Less lethal to others.
"You're talking about a biological weapon," the Trader said.
"I'm talking about a tool. What people do with it is their business."
The Trader thought about the implications. A virus that could kill only certain ethnic groups. That could be deployed silently, invisibly, without attribution.
"How much do you need?"
"Five million. To start."
The Trader arranged the funding. He moved the money through shell companies and numbered accounts, ensuring that no trace led back to Duvalier—or to himself.
THE LAB
Duvalier's lab was in a converted factory outside Geneva.
It had no sign, no name, no indication of its purpose. The windows were blacked out. The doors were reinforced steel. The staff—a dozen scientists and technicians—came and went at odd hours, speaking in whispers.
The Trader visited once, out of curiosity. Duvalier gave him a tour, pointing out equipment whose purpose the Trader could only guess.
"This is where we culture the virus," Duvalier said, gesturing toward a row of incubators. "And this is where we test it."
"Test it on what?"
Duvalier opened a door to another room. Inside, cages lined the walls. Mice, rats, rabbits. Some were healthy. Some were clearly sick—lethargic, trembling, their fur matted.
"We use animals, of course. For now."
The Trader understood. For now.
"And when you're ready for human trials?"
Duvalier smiled. "There are always volunteers. The poor. The desperate. The forgotten. No one asks questions."
The Trader thought about the donors in Nigeria. The villagers who sold their kidneys for five hundred dollars. He thought about how easily the same system could be used for something far worse.
He added a note to his ledger.
III. THE TARGET
In 2009, Duvalier achieved a breakthrough.
He had developed a strain of influenza that could be modified to target people with a specific genetic marker—a marker common in certain populations of sub-Saharan Africa. In lab tests, it killed 80% of infected subjects within two weeks.
Duvalier was ecstatic. The Trader was horrified.
"You've created a weapon that could wipe out millions," the Trader said.
"I've created a tool. What others do with it is not my concern."
"Who have you told about this?"
Duvalier hesitated. "There are interested parties. Governments. Foundations. People who understand the value of what I've created."
The Trader felt a chill. "Which governments?"
"I cannot say. But they are willing to pay. Handsomely."
The Trader demanded to see the offers. Duvalier showed him documents—proposals from entities he did not recognize, with names that meant nothing. But the money was real. Millions of dollars, offered for the rights to Duvalier's research.
The Trader advised him to be careful. Duvalier laughed.
"I am always careful."
THE SALE
In 2011, Duvalier sold his research.
The buyer was a consortium of private investors, represented by lawyers the Trader did not know. The price was fifty million dollars—ten times what the Trader had helped raise. Duvalier retired to a villa in the south of France, wealthy beyond his dreams.
The Trader never learned who the buyers were. The documents were sealed. The transactions were hidden. The trail went cold.
But he kept the notes he had made. Names, dates, amounts. The genetic markers Duvalier had targeted. The lab where the work was done.
He added them to his ledger.
THE OUTBREAK
In 2020, a novel coronavirus emerged in Wuhan, China.
The world watched as it spread—first across Asia, then Europe, then the Americas. Millions died. Economies collapsed. Governments imposed lockdowns, mandates, restrictions.
The Trader watched from his apartment in Geneva. He saw the news, the panic, the fear. He saw the scientists on television, explaining the origins of the virus, the mutations, the spread.
He thought about Duvalier. About the lab outside Geneva. About the genetic markers and the targeted strains.
He took out his ledger and read through the entries from 2005 to 2011.
Then he wrote a new entry.
January 2020 — Wuhan virus emerges. Possibly natural. Possibly not. Duvalier's research sold to unknown buyers in 2011. Genetic targeting similar to his work. No proof. But no coincidence either.
THE COINCIDENCE
Over the following months, the Trader investigated.
He contacted old associates, dug through archives, followed money trails. He discovered that one of the shell companies involved in Duvalier's sale had connections to a Chinese research institute. Another had ties to a American biodefense laboratory. A third was linked to a European pharmaceutical giant.
He could not prove anything. The connections were tenuous, the evidence circumstantial. But the pattern was there, if you knew how to look.
He added more notes to his ledger. Names, dates, transactions. Nothing conclusive. But enough to raise questions.
Enough to make him wonder if the virus that killed millions had been born in a lab, funded by money he had helped move.